Circadian swallows Vegenics

By Dylan Bushell-Embling
Tuesday, 15 July, 2008

Circadian Technologies [ASX: CSR] is to acquire 100 per cent ownership of Vegenics as part of its strategy to transform Circadian from a biotech incubator to a full-scale drug development company.

Under the agreement, Circadian is to purchase the 33 per cent share owned by Vegenics co-founders the Ludwig Institute for Cancer Research and Licentia Limited.

Circadian will assume complete control of the rights to and development of Vegenics' VEGF technology.

In return, Circadian will give the Ludwig Institute and Licentia shares totalling 11 per cent ownership of the company, with more shares on offer once certain product development milestones are met.

Related News

Does exercise really extend lifespan? It's complicated

Physical activity is seen as a way to extend the human lifespan, but the benefits of physical...

Nature helps to relieve physical pain

Experiencing nature, even in the form of watching nature videos, can alleviate acute physical pain.

SEQ koala population carries immunity to retrovirus

Koalas from a population north of the Brisbane River appear to have evolved a unique genomic...


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd